Ardent Health, Inc. filings document the formal reporting record for a public healthcare provider operating acute care hospitals and related sites of care through subsidiaries. Form 8-K disclosures furnish quarterly operating results, including revenue, admissions measures, net patient service revenue, adjusted EBITDA, and related non-GAAP reconciliations.
The filing record also covers governance and capital-structure matters. Proxy materials describe annual-meeting proposals, director elections, executive compensation, equity awards, and pay-versus-performance data. Other 8-K filings report executive-separation and severance arrangements, a common stock repurchase authorization, and amendments to term loan and asset-based lending credit agreements involving subsidiary borrowers and guarantors.
Ardent Health, Inc. operates a network of 30 acute care hospitals and approximately 280 sites of care across six states with 1,875 employed and affiliated providers as of June 30, 2025. The company uses a joint-venture model in which it is typically the majority owner and day-to-day operator, partnering with academic and not-for-profit systems to expand market presence and clinical services. EGI-AM Investments, L.L.C. owned approximately 54.0% of outstanding common stock, making EGI-AM the company’s controlling stockholder under NYSE rules. The filing discloses a table of selling stockholders showing large share blocks (for example, 77,246,499 shares representing 54.0%) and various other holders with specified share counts and percentages. The prospectus lists exhibits, underwriting and legal opinions, audit consents from Ernst & Young LLP, and a registration fee table.
Ardent Health, Inc. (NYSE: ARDT) filed an 8-K disclosing the immediate departure of David Schultz, President, Hospital Operations, effective June 16 2025. The company classified the exit as a “Qualifying Termination” under its Executive Severance Plan, making Mr. Schultz eligible for severance payments and related benefits, subject to standard plan conditions such as non-compete and non-solicitation covenants.
The filing provides no quantitative detail on payout size, claw-back triggers, or succession plans. Mr. Schultz had overseen the hospital segment, a core operating unit that drives the majority of Ardent’s revenue. Governance protocol appears to have been followed—compensation terms reference disclosures in the April 8 2025 proxy statement and the Q2 2024 10-Q exhibit that contains the Severance Plan.
Investment relevance:
- Unanticipated C-suite turnover can disrupt execution of operational initiatives, regulatory compliance, and cost-containment programs, potentially affecting near-term margin trajectory.
- Because no interim or permanent replacement was announced, investors face visibility risk on leadership continuity in hospital operations.
- Cash severance outflows could be modest relative to Ardent’s scale, but exact magnitude is not provided, limiting assessment of liquidity impact.